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Abstract Öz 
Purpose: Hematopoietic stem cell (HSC) engraftment is 
influenced by many factors.  We investigated the effects of 
bone marrow fibrosis and angiogenetic structure on 
engraftment in patients with hematological malignancies.  
Materials and Methods: Data were collected from 34 
patients (20 males and 14 females) who underwent 
autologous HSC transplantation. Bone marrow 
myelofibrosis was graded from 0 to 3, angiogenesis was 
quantified using a stereological method in the most recent 
bone marrow biopsy before the transplantation. Patients 
were categorized into two groups according to intensity of 
angiogenesis parameters.  
Results: Half of the patients had fibrosis and majority had 
multiple myeloma (73.5%). Eleven patients had grade 1, 
six had grade 2 myelofibrosis. The engraftment day (ED) 
for platelets and erythrocytes was significantly different 
between the grade 2 fibrosis and non-fibrosis groups. VSD 
and NVES levels were significantly higher in the grades 1 
and 2 fibrosis groups than the no fibrosis group. While the 
overall survival time was shorter in the grade 2 fibrosis 
group than the others, the difference was not statistically 
significant. 
Conclusion: Bone marrow fibrosis was found to be 
independent risk factor. It may have a negative effect on 
platelet and erythrocyte engraftment time of autologous 
transplantation process but this effect does not influence 
survival.  
Amaç: Birçok faktör hematopoetik kök hücre (HKH) 
engraftmanını etkiler. Bu çalışmada hematolojik kanseri 
olan hastalarda kemik iliğindeki myelofibrozis ve 
anjiogenezisin engraftman üzerine etkisi araştırılmıştır. 
Gereç ve Yöntem: Otolog kök hücre nakli yapılan 34 
hasta (20 erkek, 14 kadın) verileri değerlendirildi. Nakilden 
önceki son kemik iliğindeki fibrozis 0-3 arasında 
derecelendirildi, anjiogenezis stereolojik metod ile ölçüldü. 
Hastalar anjiogenezis parametrelerinin yoğunluğuna göre 
de iki gruba ayrıldı. 
Bulgular: Hastaların çoğunluğu (%73.5) multipl myelom 
idi ve yarısında fibrozis saptandı. On bir hasta derece 1, 6 
hasta derece 2 fibrozise sahipti. Trombosit ve eritrosit 
engraftman günleri açısından derece 2 fibrozisi olan grupla 
fibrozis saptanmayan grup arasında istatistiksel anlamlı 
farklılık vardı. Derece 1 ve 2 fibrozis gruplarında fibrozisi 
olmayanlara göre VSD ve NVES düzeyleri anlamlı olarak 
yüksekti. Toplam yaşam derece 2 fibrozisi olan grupta 
daha düşük olmakla birlikte istatistiksel anlamlılık yoktu. 
Sonuç: Kemik iliği myelofibrozisinin bağımsız bir risk 
faktörü olduğu saptanmıştır. Bunun toplam yaşamı 
etkilemeden otolog nakil sürecinde trombosit ve eritrosit 
engraftmanı üzerine negatif etkisi olabilir. Fibrozisin 
derecesi ile doğru orantılı olarak artmış anjiogenezis 
arasındaki ilişkiyi açıklamak için ileri çalışmalar gereklidir. 
Key words: Bone marrow fibrosis, angiogenesis, 
autologous transplantation, multiple myeloma. 
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INTRODUCTION 
One of the most important criteria for successful 
autologous stem cell transplantation is overcoming 
aplasia of bone marrow that occurs due to the 
conditioning regimen. Recovery of bone marrow 
and reconstitution of hematopoiesis with re-infused 
autologous stem cells is called engraftment. 
The period of engraftment is expected to be 7–21 
days after transplantation. If the duration is > 21 
days, it indicates an engraftment delay. Engraftment 
failure is defined as > 42 days1-3. Bone marrow 
consists of hematopoietic and stromal 
compartments composed of reticular cells, 
adipocytes, and osteogenic bone cells near the 
surfaces of vascular endothelial cells, vascular 
endothelial smooth muscle cells, and 
macrophages4,5. The “hematopoietic stem cell 
niche” was first defined by Schofield in 1978. Stem 
cells are located in this micro-anatomic region of 
bone marrow where they are blocked from 
differentiating or self-renewing. The stem cells are 
supported by adjacent stromal cells.  
Hematopoietic stem cells (HSCs) and hematopoietic 
progenitor cells are distributed randomly in the bone 
marrow but are rather close to the bone 
endosteum6-8. Recent studies have demonstrated 
that they accumulate around blood vessels9,10. The 
differentiation and maturation processes of bone 
marrow HSCs were described by Shacney in 197511. 
The area where HSCs are located is rich in 
vascularization and closer to the centre of bone 
marrow. Shacney also noted that undifferentiated 
cells are found throughout the endosteum. 
The endosteal bone marrow sinusoidal network 
zone defines a different anatomical and functional 
structure and was adapted to the “vascular niche” 
concept. Ultrastructural studies have shown that 
differentiated HSCs are located closer to bone 
marrow microvascular structures compared to 
immature HSCs12,13. HSC engraftment is a complex 
process that entails the collection of circulating bone 
marrow HSCs throughout the microvascular 
structure and subsequent trans-endothelial migration 
to the bone marrow hematopoietic cords. These 
events are referred to as HSC homing. Then, stem 
cells settle to a specific region known as the niche, 
which defines lodgment14. 
These findings indicate that the interaction between 
progenitor cells and stromal cells is a critical 
determinant of the course of HSC maturation. Many 
factors that affect engraftment kinetics have been 
examined in patients undergoing autologous 
peripheral blood stem cell transplantation; however, 
the debate over engraftment process continues.  
In the present study, we investigated the effects of 
bone marrow fibrosis and angiogenesis on 
engraftment. 
MATERIAL AND METHODS 
Patients  
This study was planned as a single-center, cross-
sectional and retrospective study. Patients who 
underwent autologous peripheral stem cell 
transplantation (PSCT) over 6 years were enrolled in 
this retrospective study. Study material was collected 
from the records starting on January 2003 and 
ending at December 2008. Pre-transplant bone 
marrow biopsies obtained from 34 consecutive 
patients (20 males and 14 females) were examined. 
Sections from paraffin blocks were placed on poly 
L-lysine slides, preserved in the Pathology 
Department archive, and were evaluated by two 
hematopathologists. Marrow structure was 
examined fibrotic and angiogenetic structure. 
Patients were grouped according to the degree of 
fibrosis.  
Diagnosis, disease stage, treatment, response, total 
number of CD34+ peripheral stem cells (PSCs) 
collected, mobilization regimen, pre-transplant 
disease status, and the last date of contact or date of 
death were recorded from the patient files. 
Neutrophil, platelet and erythrocyte engraftment day 
were noted. 
Primary endpoint was defined as neutrophil, platelet 
and erythrocyte engraftment time associated with 
bone marrow structure. Secondary endpoint was the 
effect of marrow structure on survival. 
Ethics committee approval was obtained from the 
Institutional Ethics Committee prior to the study. 
Informed consent was obtained from all individual 
participants included in this study.  
Definitions 
Neutrophil engraftment day (ED) was defined as 
the first day that the neutrophil count remained ≥ 
500 × 106/L. Platelet engraftment had occurred 
when the platelet count was > 20 × 109/L for 7 
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days without a transfusion. Erythrocyte engraftment 
required an interval of 3 weeks without a blood 
transfusion1. 
Angiogenesis was evaluated by using the CD34 
(NeoMarkers, Freemont, CA, USA) antigen 
streptavidin-avidin-immunoperoxidase method. 
Stereological measurements were performed to 
determine the vascular density visible with CD34. 
Number of vessels per unit stroma (NVES) and 
vascular surface density (VSD) per tumor tissue 
volume were calculated according to the following 
formulae15. 
𝑉𝑉𝑉𝑉𝑉𝑉 = 𝛴𝛴𝛴𝛴𝛴𝛴.2.121
𝐼𝐼𝐼𝐼𝑡𝑡𝑡𝑡.𝐿𝐿𝑡𝑡    𝑁𝑁𝑉𝑉𝑁𝑁𝑉𝑉 = 𝑁𝑁.121𝐼𝐼𝐼𝐼𝑡𝑡𝑡𝑡  
The sections were fixed at 100× magnification for 
light microscopy and reflected on a camera (CCD; 
Sony, Tokyo, Japan) and monitor (Sony Trinitron). 
A 525× magnified image was also obtained. The 
image was placed on a transparent monitor 
composed of 121 points formed by 11 horizontal 
and 11 vertical test lines. The tumor tissue was 
contained within the borders of the transparent area, 
and the number of junction points where the vessels 
crossed test lines (In) were noted as the total vessel 
count (N) whether they crossed or not. Vv (str) 
indicates the stromal volume ratio above the test 
line and was determined by the point-counting 
method. Vv (str) is the point count per stroma 
divided by 121. The same process was repeated in 
10 randomly selected fields. Lr (constant number), 
10.34; Istr, number of crossed horizontal and 
vertical lines in the specified stromal field. 
Myelofibrosis was graded based on the European 
Consensus Report of Bone Marrow Fibrosis grading 
of 0–3 in sections treated with reticulin silver and 
Masson’s trichrome stains16.  All patients received 
2.4 g/m2 cyclophosphamide and a granulocyte 
colony stimulating factor protocol to mobilize the 
stem cells. The conditioning regimen was melphalan 
for multiple myeloma and BEAM (carmustine, 
etoposide, ARA-C, and melphalan) for lymphoma.  
The patients were classified into three groups 
according to CD 34 level, fibrosis based on 
literature. Furthermore, patients were classified into 
two groups with regard to intensity of angiogenetic 
parameters. 
Statistical analysis 
Continuous variables between the groups were 
analysed using the Mann–Whitney U or Kruskal–
Wallis tests. Correlations between continuous 
variables were detected using Spearman’s correlation 
test. Linear regression models were performed to 
determine the independent risk factors related with 
neutrophil, platelet, and erythrocyte engraftment 
days.  
Table 1. Pre-transplantation characteristics of the patients 
Characteristic Patients # % 
Diagnosis   
  Multiple Myeloma 24 70.6 
  Non-Hodgkin lymphoma 5 14.7 
  Hodgkin lymphoma 4 11.8 
  Plasmacytoma 1 2.9 
Remission status   
  VGPR 7 20.6 
  PR 23 67.6 
  SD 2 5.9 
  ResD 1 2.9 
  RefD 1 2.9 
No. CT regimens   
  0–1 20 58.8 
  > 1 14 41.2 
Radiotherapy   
  Yes  18 52.9 
  No  16 47.1 
No. CT: number of prior chemotherapy regimens, VGPR: Very good partial remission,  PR: partial remission, SD: stabile disease, 
ResD: residual disease, RefD: refractory disease 
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The predictors of time to transplantation and overall 
survival rate were analysed using the Kaplan–Meier 
method and compared to the Mantel log-rank test. 
Results are reported as median (range), number (n), 
and percent (%). A p-value < 0.05 was considered 
significant. Statistical analyses were performed using 
the SPSS v 20.0 software package (SPSS Inc., 
Chicago, IL, USA). 
RESULTS 
The median age of the patients was 50 years (range, 
17–70 years). Most patients were diagnosed with 
multiple myeloma (73.5%), and disease status was 
partial remission in 67.6%. Of all patients, 55% had 
received only one line of chemotherapy (CT) before 
transplantation and 45% had received two or more 
lines of CT. The pre-transplantation characteristics 
of the patients are shown in Table 1. The patients 
were divided into three groups based on CD34+ cell 
level. The CD34+ cell levels were < 5 × 106/kg, 5–
9.9 × 106/kg, and ≥ 10 × 106/kg in groups 1, 2, and 
3 respectively. No differences were found in terms 
of the numbers of neutrophil, platelet, or 
erythrocyte EDs among these three groups (Table 
2). There were no statistically significant differences 
among CD 34+groups with regard to age, disease 
status, receiving radiotherapy, fibrosis and 
angiogenetic parameters (p>0,05 for all) 
A correlation analysis was performed between for 
the numbers of neutrophil, platelet, and erythrocyte 
EDs in each CD34+ groups.  As a result, no 
significant correlation was detected between CD34+ 
cell level and the numbers of neutrophil or 
erythrocyte EDs. A trend to negative correlation 
was observed between CD34+ cell level and the 
number of platelet EDs (r=−0.32, p = 0.016). 
The numbers of patients in fibrosis groups 0, 1 and 
2 were 17 (50%), 11 (32.4%), and 6 (17.6%), 
respectively. No patient had grade 3 fibrosis. A 
significant difference was detected in the number of 
platelet and erythrocyte EDs between the groups 
(p=0.037 and p=0.010, respectively). The median 
numbers of platelet and erythrocyte EDs were 
similar in patients with grades 0 and 1, but these 
durations were significantly longer in the grade 2 
fibrosis group than in the other groups. However, 
the number of neutrophil EDs was not different 
(p=0.257) among the three fibrosis groups. The 
median levels of the angiogenesis parameters (VSD 
and NVES) increased as the degree of fibrosis 
increased. Significant differences were detected in 
the VSD and NVES among the fibrosis groups 
(p=0.034 and p=0.028, respectively). The median 
VSD and NVES levels were similar in patients with 
grades 1 and 2 fibrosis, but the median levels were 
significantly lower in grade 0. A post-hoc test was 
not applied between the fibrosis subgroups due to 
insufficient sample size.  
No correlations were found between VSD, NVES, 
and the numbers of neutrophil, platelet, and 
erythrocyte EDs (r<0.20 for all). Angiogenesis was 
evaluated as number of micro vessel count per field 
(NVES) and vascular surface density (VSD) per 
tumor tissue volume. Median was detected as 35,4 
(min:4,02 max:112,3) mm-2 for VSD and 92,8 
(min:10,3- max:325,7) mm-1 for NVES. Patients 
were categorized into two groups according to 
median levels of VSD and NVES. VSD levels of 
≤35,4  mm-2  and >35,5  mm-2 were classified as 
Group 1 and Group 2, respectively. Similarly, NVES 
values of ≤92,9 mm2and ≥93 mm-2 were classified 
as Group 1 and Group 2, respectively. A statistically 
significant difference was not detected neither 
among VSD groups nor NVES groups in terms of 
neutrophil, platelet and erythrocyte engraftment 
days (Table 2). 
Mean overall survival was 53.7 months (95% 
confidence interval [CI], 40.5–66.9 months) and 
mean time to transplantation was 34.0 months (95% 
CI, 24.7–43.3 months) (Table 3). Overall survival 
was lower in grade 2 compared to grade 1 patients 
(28.3 vs. 58.4 months). Similar results were observed 
among patients with fibrosis grades 1 and 2 for time 
to transplantation (34 vs. 16 months, respectively) 
(Table 3, Figure 1).  Cox regression models were not 
performed to determine the independent risk factors 
related with neutrophil, thrombocyte and 
erythrocyte engraftment days due to insufficient 
sample size. 
Three linear regression models were performed: 
neutrophil , platelet, and erythrocyte engraftment 
days were used as dependent variable; VSD, CD 34+ 
cell amount measured as continuous variables; 
fibrosis and disease status at pre-transplantation 
were used as independent variables in the separately 
models. The results of linear regression models 
showed that fibrosis was found to be significantly 
independent factor related with platelet and 
erythrocyte engraftment days (p=0.037 and p 
<0.001 respectively).  
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Table 2. The neutrophil, thrombocyte and erythrocyte engraftment days in severalgroups 
Median (min-max) Neutrophil 
engraftment days 
Thrombocyte 
engraftment days 
Erythrocyte 
engraftment days 
CD34+ cell groups    
  1 (n:12) 11.5 (9-19) 16.5 (10-35) 13.0 (9-35) 
  2 (n:11) 11.0 (9-12) 12.0 (10-24) 14.0 (9-32) 
  3 (n:11) 10.0 (8-13) 12.0 (8-18) 12.0 (3-27) 
p value 0.148 0.247 0.714 
Fibrosis grade groups    
  0 (n:17) 10 (8-14) 12 (9-34) 11 (3-30) 
  1 (n:11) 11 (9-19) 12 (8-35) 12 (9-35) 
  2 (n:6) 11.5 (10-14) 18 (14-24) 22.5 (14-32) 
p value 0.257 0.037 0.010 
Fibrosis groups    
  No fibrosis (n:17) 10 (8-14) 12 (9-34) 11 (3-30) 
  Fibrosis (n:17) 11 (9-19) 15 (8-35) 14 (9-35) 
p value 0.122 0.071 0.074 
VSD groups    
  1 (n:17) 11 (9-14) 12 (8-35) 12 (3-35) 
  2 (n:17) 11 (8-19) 15 (10-23) 14 (7-27) 
p value 0.623 0.376 0.615 
NVES groups    
  1 (n:17) 11 (9-19) 12 (8-35) 12 (3-35) 
  2 (n:17) 11 (8-14) 14 (10-23) 14 (7-27) 
p value 0.806 0.972 0.603 
NVES: Micro vessel count per field, VSD: vascular surface density per tumor tissue volume. 
 
While vascular surface density per tumor unit was 
found to be significantly independent factor for 
erythrocyte engraftment day (p=0.025), CD 34+ cell 
amount was found to be significantly independent 
factor for platelet and neutrophil engraftment day 
(p=0.004 and p=0.020 respectively). 
DISCUSSION 
It is quite important to determine the hematopoietic 
engraftment rate and long-term continuity of 
engraftment following peripheral stem cell 
transplantation. Mortality and morbidity risks, 
transfusion and antibiotic needs, hospital stay 
duration, and economic costs of engraftment make 
this condition critical. 
The number of CD34+ cells in a graft is one of the 
factors affecting its kinetics. The required number of 
HSCs for autologous transplantation is 2.5–5×106 
CD34+/kg according to some authors17-20. 
However, Maunier et al.21  found that the optimal 
level was a minimum of 5×106 CD34+/kg in a study 
that investigated the influence of CD34+ cell 
number (before cryopreservation and when melted) 
on long-term hematologic reconstruction following 
autologous stem cell transplantation in patients with 
lymphoma. Furthermore, Hohaus et al.22 showed 
that platelet engraftment is faster in patients with 
lymphoma, if the number of infused CD34+ cells is 
> 5×106/kg. Our results show a similar number of 
EDs for neutrophils, platelets and erythrocytes 
regardless of the CD34+ cell count.  
There are some evidences that marrow fibrosis can 
delay in stem cell engraftment time in patients with 
acute and chronic leukaemia. Soll et al.23  
investigated the role of myelofibrosis in 203 patients 
with myelofibrosis and 203 controls. No difference 
in the number of neutrophil EDs was reported, but 
platelet engraftment was delayed 3 days in the 
myelofibrosis group. This result was a 7-day interval 
in the severe myelofibrosis group (grades 3–4) for 
platelet engraftment. Those authors also found a 
delay of 2 days for erythrocyte engraftment; 
however, the transfusion requirement was not 
different. In contrast, Scott et al.24  investigated 
patients with acute myeloid leukaemia and advanced 
myelodysplastic syndrome with multi-lineage 
dysplasia (471 patients: 113 with myelofibrosis and 
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358 without fibrosis), and detected severe fibrosis in 
28% of the patients. Neutrophil engraftment was 
observed in 98 of 113 patients, and the median ED 
was day 28 (range, 10–80 days) in these patients and 
day 17 (range, 10–33 days) in the cases without 
fibrosis. 
Table 3. Survival analyses in fibrosis and angiogenesis groups 
 Mean Overall Survival 
(month) 
Mean Time to 
Transplantation (month) 
Total n / Events n 
(% of alive) 
Fibrosis grade groups 
  0 (n:17) 65.6 41.1 17/5 (70.6) 
  1 (n:11) 58.4 34.9 11/4 (63.6) 
  2 (n:6) 28.3 16.4 6/3 (50.0) 
 p value* 0.469 0.364  
Fibrosis groups 
  No fibrosis (n:17) 65.6 41.1 17/5 (70.6) 
  Fibrosis (n:17) 50.2 29.3 17/7 (58.8) 
 p value* 0.801 0.452  
VSD groups 
  1 (n:17) 61.565 36.8 5/12 (70.6) 
  2 (n:17) 45.036 18.3 7/10 (58.8) 
 p value* 0.409 0.258  
Overall 53.7 34.0 34/12 (64.7) 
*: Log rank 
 
 
These results indicate a significant delay in the 
fibrosis group (p≤0.0001). We found a delay in 
platelet and erythrocyte engraftment time in patients 
with fibrosis. Our results reveal that the engraftment 
delay becomes more prominent as fibrosis grade 
increases. Although angiogenesis processes of many 
diseases have been investigated, particularly those 
for solid tumours, their influence on transplantation 
kinetics have not been sufficiently evaluated. Some 
evidence of vascular support for the malignant 
process can be seen in the bone marrow of patients 
with hematologic cancers, as in other solid organ 
tumours 25,26. Angiogenesis was evaluated in the 
bone marrow of patients with polycythemia vera, 
chronic myeloid leukaemia and myelofibrosis, and 
the results showed that neovascularisation increased 
in the patients with myeloproliferative diseases. The 
vascular density of bone marrow was statistically 
significant in patients with myelofibrosis (5.9±2.1 
and 14.4±5.5, respectively, p<0.001).  
According to a novel pathogenic hypothesis for 
myelofibrosis with myeloid metaplasia, 
megakaryocytes and/or monocytes clonally increase 
due to abnormal levels of cytokines released from 
impaired bone marrow stroma 27 leading to collagen 
fibrosis and new bone formation. This impaired 
stromal microenvironment also serves as a source of 
angiogenetic cytokines, such as increased expression 
of vascular growth factor by megakaryocytes28.Our 
results show that only erythrocyte engraftment is 
influenced by the VSD. This result is consistent with 
the hypothesis mentioned above. We suggest that 
angiogenesis may help alleviate the negative effects 
of fibrosis, although no direct effect on engraftment 
was shown.  
 
Figure 1: Kaplan Meier curves according to fibrosis grade groups (a), fibrosis groups (b) and VSD groups (c). 
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Regarding survival, one study investigated the 
influence of fibrosis on ED and overall survival in 
19 patients with fibrosis who underwent autologous 
transplantation. There was no difference in overall 
survival between the groups with and without 
fibrosis and the results according to fibrosis grade 
were not evaluated in that study29. We showed no 
statistically significant difference in survival by grade 
of fibrosis. 
In conclusion, bone marrow fibrosis accompanying  
multiple myeloma and lymphoma was detected to be 
an independent risk factor which negatively affects 
platelet and erythrocyte engraftment time, but this 
effect does not influence overall survival.  
Preliminary findings in this study also revealed 
angiogenetic changes in the bone marrow occurred 
dependent from intensity of marrow fibrosis.  The 
observation that VSD (part of angiogenetic 
structure) is an independent risk factor for 
erythrocyte engraftment may be an important 
preliminary data for the studies that would be 
conducted with patients group with larger sample 
size. For explaining the exact mechanism, future 
studies are needed.   
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